 Galmed Pharmaceuticals Ltd. Nasdaq: GLMD Galmed or the Company, a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3 clinical trial for the treatment of nonalcoholic steatohepatitis NASH and fibrosis announced today that it will host a conference call and webcast on Thursday, March 12, 2020, to provide an update on current developments with respect to its clinical programs for AramcholTM and to discuss financial results for the quarter and year ended December 31, 2019. 